Spruce Biosciences (SPRB) Total Current Liabilities (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Total Current Liabilities of $11.8 million for Q1 2026, down 24.78% year-over-year from $15.7 million in Q1 2025, and up 16.84% quarter-over-quarter from $10.1 million in Q4 2025.
Spruce Biosciences (SPRB) Total Current Liabilities (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Total Current Liabilities for 8 consecutive years, with $11.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 24.78% year-over-year to $11.8 million; the TTM figure through Mar 2026 stood at $11.8 million (down 24.78% YoY), while the FY2025 annual figure was $10.1 million, down 33.84% from the prior year.
- Total Current Liabilities grew to $11.8 million in Q1 2026 per SPRB's latest filing, from $10.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $24.5 million in Q4 2023 and bottomed at $8.1 million in Q2 2025.
- Historically, Total Current Liabilities has averaged $14.9 million across 5 years, with a median of $12.4 million in 2022.
- Annual changes were most pronounced in 2023 — Total Current Liabilities jumped 156.38% — and 2024, when it sank 50.98%.
- Spruce Biosciences' Total Current Liabilities stood at $12.4 million in 2022, then jumped by 96.55% to $24.5 million in 2023, then plunged by 37.68% to $15.2 million in 2024, then slumped by 33.84% to $10.1 million in 2025, then advanced by 16.84% to $11.8 million in 2026.
- Business Quant data shows SPRB's Total Current Liabilities at $11.8 million in Q1 2026, $10.1 million in Q4 2025, and $9.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 630.93 Mn |
| 10 | Spruce Biosciences | 122.59 Mn | 122.59 Mn | - | 10.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.96 Mn |
| Mar 31, 2026 | 11.78 Mn |
| Dec 31, 2025 | 10.09 Mn |
| Sep 30, 2025 | 9.43 Mn |
| Jun 30, 2025 | 8.06 Mn |
| Mar 31, 2025 | 15.67 Mn |
| Dec 31, 2024 | 15.25 Mn |
| Sep 30, 2024 | 11.86 Mn |
| Jun 30, 2024 | 14.29 Mn |
| Mar 31, 2024 | 18.39 Mn |
| Dec 31, 2023 | 24.47 Mn |
| Sep 30, 2023 | 24.19 Mn |
| Jun 30, 2023 | 22.73 Mn |
| Mar 31, 2023 | 23.00 Mn |
| Dec 31, 2022 | 12.45 Mn |
| Sep 30, 2022 | 12.00 Mn |
| Jun 30, 2022 | 10.10 Mn |
| Mar 31, 2022 | 8.97 Mn |
| Dec 31, 2021 | 8.87 Mn |
| Sep 30, 2021 | 9.06 Mn |